An interventional study of G-CSF (Granulocyte colony-stimulating factor) in Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Healthy donors are commonly mobilized with granulocyte colony-stimulating factor (G-CSF) to collect peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the efficiency of mobilization varies among donors, and suboptimal mobilization may require additional collection procedures or rescue strategies. This prospective, multicenter, randomized trial evaluates whether the timing of daily G-CSF administration (morning vs evening) affects the level of circulating CD34+ cells in healthy donors. Participants will be randomly assigned to receive subcutaneous G-CSF once daily for 4-5 consecutive days either at 08:00 (±15 minutes) or at 20:00 (±15 minutes). The goal of the study is to identify a practical dosing schedule that may improve stem cell mobilization and streamline donor collection procedures.
The study protocol was substantially amended following approval by the Institutional Review Board. The amendments included revisions to the G-CSF administration regimen, the primary and secondary outcome measures, and the assessment schedule. Enrollment under the revised protocol commenced on 1st Nov. Participants enrolled under the previous protocol version will be documented separately and will not be included in the prespecified primary analysis of the revised-protocol cohort.
Background and Rationale
Peripheral blood stem cell collection after G-CSF mobilization is the most widely used donation approach for allo-HSCT. Donor mobilization outcomes exhibit inter-individual variability, and donors with lower circulating CD34+ levels may require longer processing volumes, additional collection days, or rescue mobilization. Circadian biology may influence hematopoietic cell trafficking and cytokine responses, suggesting that the administration timing of G-CSF could affect mobilization intensity and collection efficiency. This trial tests whether a simple, operational change in dosing time can improve pre-apheresis CD34+ levels in healthy donors.
Study Design
This is a prospective, multicenter, stratified randomized controlled trial with two parallel arms. The study is open-label due to the nature of the intervention (fixed dosing times), while the statistician will remain blinded to group allocation until database lock. Allocation is stratified by donor age (\<40 vs ≥40 years) and sex to balance key donor characteristics across arms.
Interventions and Procedures
Eligible healthy donors will receive subcutaneous G-CSF at 10 μg/kg once daily for 4-5 consecutive days (Day 1 to Day 5, according to the first day collection efficacy), assigned to one of the following schedules:
Morning group: 08:00 (±15 minutes) each day
Evening group: 20:00 (±15 minutes) each day
The first apheresis session is scheduled to begin after the forth G-CSF dose. Collection targets are based on recipient weight, with standard operational procedures for conducting a second collection day if the first-day yield does not meet the target. If peripheral blood CD34+ is low after the final G-CSF dose, centers may apply rescue mobilization per local practice, and such use will be recorded for sensitivity analyses.
Outcome Measures Primary Outcome: To compare peripheral blood CD34+ cell counts (cells/μL) between healthy donors receiving morning (08:00) versus evening (20:00) G-CSF administration, measured at a standardized clock time of 11:30 (±15 minutes), after the fourth G-CSF dose and immediately before the first apheresis session.
Sample Size and Analysis Overview A total of 160 donors (80 per group) will be enrolled to provide adequate power for detecting clinically meaningful differences in the primary endpoint while allowing for non-evaluable cases. The primary analysis will follow the intention-to-treat principle, with additional per-protocol and sensitivity analyses as appropriate, including analyses accounting for rescue mobilization when applicable.
Safety Monitoring and Follow-up Donors will be monitored with clinical assessment and routine laboratory testing during the mobilization period and on collection days. Adverse events commonly associated with G-CSF (e.g., bone pain) and donation-related events will be recorded and managed per standard-of-care practices. Donors will be followed through approximately Day 30 to capture delayed or persistent adverse events.
First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
7.5 μg/kg subcutaneous once daily for 4-5 days at 08:00 ± 15 min
Drug: G-CSF (Granulocyte colony-stimulating factor)
7.5 μg/kg subcutaneous once daily for 4-5 days at 20:00 ± 15 min
Drug: G-CSF (Granulocyte colony-stimulating factor)
Subcutaneous recombinant human G-CSF (7.5 μg/kg once daily) administered for 4 consecutive days. Participants are assigned to a fixed dosing time: 08:00 (±15 minutes) or 20:00 (±15 minutes).
Peripheral Blood CD34+ Cell Count before the first apheresis session
Peripheral blood CD34+ cell count (cells/μL) measured at a fixed clock time of 11:30 (±15 minutes), after the fourth G-CSF dose and immediately before the first apheresis session, scheduled to begin at 12:00 in both treatment groups. CD34+ cell counts will be determined using standardized flow cytometry procedures.
Time frame: After the fourth G-CSF dose, immediately before the first apheresis session (11:30 ±15 minutes).
Peripheral Blood CD34+ Cell Count 12 Hours After the Third G-CSF Dose
Peripheral blood CD34+ cell count (cells/μL) measured 12 (±1) hours after the third G-CSF dose, before any apheresis procedure. CD34+ cells will be enumerated using standardized flow cytometry procedures.
Time frame: 12 (±1) hours after the third G-CSF dose, before the first apheresis session.
CD34+ Cell Yield During the First Apheresis Session
Total number of CD34+ cells collected during the first apheresis session, normalized to donor body weight and expressed as ×10⁶ CD34+ cells/kg.
Time frame: At completion of the first apheresis session following the fourth G-CSF dose.
Peripheral Blood CD34+ Cell Count before the second apheresis session
Peripheral blood CD34+ cell count (cells/μL) measured at a fixed clock time of 11:30 (±15 minutes), after the fifth G-CSF dose and immediately before the second apheresis session, scheduled to begin at 12:00 in both treatment groups. CD34+ cell counts will be determined using standardized flow cytometry procedures.
Time frame: After the fifth G-CSF dose, immediately before the second apheresis session (11:30 ±15 minutes).
Peripheral Blood CD34+ Cell Count 12 Hours After the Fourth G-CSF Dose
Peripheral blood CD34+ cell count (cells/μL) measured 12 (±1) hours after the fourth G-CSF dose using standardized flow cytometry procedures.
Time frame: 12 (±1) hours after the fourth G-CSF dose, regardless of the timing of the first apheresis session.
G-CSF Dose Escalation
Proportion of donors requiring an increase in the daily G-CSF dose above the protocol-specified 10 μg/kg/day because of inadequate mobilization or insufficient CD34+ cell yield. Routine administration of an additional fifth G-CSF dose without increasing the daily dose will not be classified as dose escalation.
Time frame: From the first apheresis session until completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
Proportion of Donors Requiring Plerixafor Rescue Mobilization
Proportion of donors receiving plerixafor rescue mobilization because of inadequate peripheral blood CD34+ mobilization or insufficient collection yield, according to prespecified rescue criteria.
Time frame: From the first G-CSF dose through completion of the final apheresis session, typically within 2 days and up to 3 consecutive days of apheresis.
Incidence of Adverse Events in Healthy Donors
Incidence and severity of adverse events associated with G-CSF mobilization, apheresis procedures, and rescue mobilization, including bone pain, headache, fatigue, citrate-related reactions, and vascular access complications. Adverse events will be assessed according to the protocol-specified grading system.
Time frame: From the first G-CSF dose through 30 days after the final apheresis session.
Time to Neutrophil Engraftment After Transplantation
Time from stem cell infusion to neutrophil engraftment in transplant recipients, defined as the first of three consecutive days with an absolute neutrophil count ≥0.5 × 10⁹/L. Death before engraftment will be treated as a competing event in exploratory analyses.
Time frame: From transplantation (Day 0) through Day 100 after transplantation.
Time to Platelet Engraftment After Transplantation
Time from stem cell infusion to platelet engraftment in transplant recipients, defined as the first of seven consecutive days with a platelet count ≥20 × 10⁹/L without platelet transfusion during the preceding seven days. Death before engraftment will be treated as a competing event.
Time frame: From transplantation (Day 0) through Day 100 after transplantation.
Cumulative Incidence of De Novo Grade II-IV and III-IV Acute Graft-versus-Host Disease
Cumulative incidence of newly occurring grade II-IV and grade III-IV acute graft-versus-host disease (aGVHD) among transplant recipients, assessed using prespecified standard grading criteria. Competing events will be handled using competing-risk methods.
Time frame: From transplantation (Day 0) through Day 100 after transplantation.
Total Number of Apheresis Sessions per Donor
Total number of apheresis sessions performed for each donor during the mobilization and collection period.
Time frame: From the first apheresis session through completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
Plan to share: No — Individual participant data will not be shared because the study involves healthy donors and contains potentially identifiable information. De-identified, aggregate results will be reported in publications and presentations. Reasonable requests for additional information may be considered by the study team on a case-by-case basis, subject to ethics approval and data governance requirements.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Mar 2026 → Nov 2026 and completion Mar 2027 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Granulocyte Colony-Stimulating Factor
First Affiliated Hospital of Zhejiang University →